Abstract
Purpose Benign breast disease (BBD) is a strong breast cancer risk factor but identifying patients that might develop invasive breast cancer remains a challenge.
Methods By applying machine-learning to digitized H&E-stained biopsies and computer-assisted thresholding to mammograms obtained circa BBD diagnosis, we generated quantitative tissue composition metrics and determined their association with future invasive breast cancer diagnosis. Archival breast biopsies and mammograms were obtained for women (18-86 years) in a case-control study, nested within a cohort of 15,395 BBD patients from Kaiser Permanente Northwest (1970-2012), followed through mid-2015. Cases (n=514) who developed incident invasive breast cancer and controls (n=514) were matched on BBD diagnosis age and plan membership duration.
Results Increasing epithelial area on the BBD biopsy was associated with increasing breast cancer risk [Odds ratio(OR) 95% confidence interval(CI) Q4 vs Q1=1.85(1.13-3.04);Ptrend=0.02]. Conversely, increasing stroma was associated with decreased risk in non-proliferative, but not proliferative, BBD (Pheterogeneity=0.002). Increasing epithelium-to-stroma proportion [OR(95%CI)Q4 vs Q1=2.06(1.28-3.33);Ptrend=0.002] and percent mammographic density (MBD) [OR(95%CI)Q4 vs Q1=2.20(1.20-4.03);Ptrend=0.01] were independently and strongly predictive of increased breast cancer risk. In combination, women with high epithelium-to-stroma proportion/high MBD had substantially higher risk than those with low epithelium-to-stroma proportion/low MBD [OR(95%CI)=2.27(1.27-4.06);Ptrend=0.005], particularly among women with non-proliferative [Ptrend=0.01] versus proliferative [Ptrend=0.33] BBD.
Conclusion Among BBD patients, increasing epithelium-to-stroma proportion on BBD biopsies and percent MBD at BBD diagnosis were independently and jointly associated with increasing breast cancer risk. These findings were particularly striking for women with non-proliferative disease (comprising ∼70% of all BBD patients), for whom relevant predictive biomarkers are lacking.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Intramural Research Funds of the Division of Cancer Epidemiology and Genetics (DCEG) of the National Cancer Institute, Department of Health and Human Services, USA. Thomas Rohan is supported by the Breast Cancer Research Foundation (BCRF-19-140). Erin Bowles is supported by the National Cancer Institute R50CA211115.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NIH/NCI/DCEG Institutional Review Board
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data underlying this article will be shared on reasonable request to the corresponding author.